Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Drop in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a large drop in short interest in the month of September. As of September 30th, there was short interest totaling 38,895 shares, a drop of 47.6% from the September 15th total of 74,269 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 64,451 shares, the short-interest ratio is currently 0.6 days.

Analyst Ratings Changes

A number of equities research analysts recently commented on DWTX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Friday, July 24th. HC Wainwright restated a “buy” rating on shares of Dogwood Therapeutics in a research note on Wednesday, September 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Price Performance

NASDAQ DWTX traded up $0.03 during trading hours on Wednesday, reaching $1.33. The company’s stock had a trading volume of 16,074 shares, compared to its average volume of 76,079. The firm has a market capitalization of $45.07 million, a price-to-earnings ratio of -0.15 and a beta of 1.92. The company’s 50-day moving average is $1.89 and its two-hundred day moving average is $1.73. Dogwood Therapeutics has a 1-year low of $1.28 and a 1-year high of $7.04.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.20). Equities analysts forecast that Dogwood Therapeutics will post -0.80 EPS for the current fiscal year.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with herpesvirus reactivation. The company’s research is aimed at addressing chronic conditions for which viral activity may contribute to symptoms and disease progression.

Dogwood’s lead investigational product is IMC-1, a fixed-dose combination of famciclovir, an antiviral medicine, and celecoxib, an anti-inflammatory drug. The therapy has been studied as a potential treatment for fibromyalgia, and the company has also evaluated its broader application in conditions such as long COVID.

The company was formerly known as Virios Therapeutics and adopted the Dogwood Therapeutics name as it expanded its focus on antiviral drug development.